Company / R&D Expense
Organogenesis Holdings Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$44.4M
FY2025
5-year range
$14.8M / $44.4M
FY2021-FY2025
Trend
+11.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 7 consecutive years, from $6M in FY2018 to $44M in FY2025.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of +32.8%.
Improved from $31M to $44M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +30.2%
- 5-Year CAGR
- +32.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Organogenesis Holdings Inc.'s r&d expense has grown for 7 consecutive years.
- 5-year CAGR of +32.8%, indicating consistent growth.
- In FY2025, r&d expense increased 11.6% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.4M | +11.6% |
| FY2024 | $39.8M | +29.3% |
| FY2023 | $30.7M | +53.1% |
| FY2022 | $20.1M | +35.7% |
| FY2021 | $14.8M | +37.8% |
| FY2020 | $10.7M | +18.5% |
| FY2019 | $9.1M | +44.4% |
| FY2018 | $6.3M | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026